Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryMay 28, 2015	Minerva Neurosciences to Present at Upcoming Investor Conferences in June	View HTML Minerva Neurosciences to Present at Upcoming Investor Conferences in June 24 KB
Toggle SummaryMay 18, 2015	Minerva Neurosciences Announces Appointment of Dr. Fouzia Laghrissi-Thode to Its Board of Directors	View HTML Minerva Neurosciences Announces Appointment of Dr. Fouzia Laghrissi-Thode to Its Board of Directors 27.8 KB
Toggle SummaryMay 7, 2015	Minerva Neurosciences Reports First Quarter 2015 Financial Results and Other Key Business Updates	View HTML Minerva Neurosciences Reports First Quarter 2015 Financial Results and Other Key Business Updates 39.7 KB
Toggle SummaryApril 30, 2015	Minerva Neurosciences to Host First Quarter 2015 Financial Results Webcast and Conference Call	View HTML Minerva Neurosciences to Host First Quarter 2015 Financial Results Webcast and Conference Call 23 KB
Toggle SummaryMarch 26, 2015	Minerva Neurosciences Reports Fourth Quarter and Full Year 2014 Financial Results	View HTML Minerva Neurosciences Reports Fourth Quarter and Full Year 2014 Financial Results 43.4 KB
Toggle SummaryMarch 19, 2015	Minerva Neurosciences to Host Fourth Quarter and Full Year 2014 Financial Results Webcast and Conference Call	View HTML Minerva Neurosciences to Host Fourth Quarter and Full Year 2014 Financial Results Webcast and Conference Call 15.6 KB
Toggle SummaryMarch 18, 2015	Minerva Neurosciences Completes Private Placement, Raises $31 Million	View HTML Minerva Neurosciences Completes Private Placement, Raises $31 Million 18.9 KB
Toggle SummaryMarch 13, 2015	Minerva Neurosciences Announces $31 Million Financing	View HTML Minerva Neurosciences Announces $31 Million Financing 19.3 KB
Toggle SummaryJanuary 21, 2015	Minerva Neurosciences Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist for Treatment of Sleep Disorders Including Primary and Comorbid Insomnia	View HTML Minerva Neurosciences Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist for Treatment of Sleep Disorders Including Primary and Comorbid Insomnia 85.1 KB
Toggle SummaryJanuary 20, 2015	Minerva Neurosciences Announces $15 Million Debt Facility With Oxford Finance LLC and Silicon Valley Bank Funding supports Minerva continuing to advance the clinical program for MIN-101, the company's investigational compound in development for treatment of schizophrenia	View HTML Minerva Neurosciences Announces $15 Million Debt Facility With Oxford Finance LLC and Silicon Valley Bank 23.7 KB

Press Releases

Shareholder Tools